STW 5 (Iberogast®)-a safe and effective standard in the treatment of functional gastrointestinal disorders
STW 5 (Iberogast®)-a safe and effective standard in the treatment of functional gastrointestinal disorders
复制标题
DOI：
10.1007/s10354-012-0169-x
复制
发表时间：
2013-02-01
影响因子：
0.9
通讯作者：
Allescher, Hans-Dieter
中科院分区：
文献类型：
--
作者：
Ottillinger, Bertram;Storr, Martin;Allescher, Hans-Dieter
功能性消化不良(FD)和肠易激综合征(IBS)是影响生活质量的常见疾病。它们通常需要长期治疗。这两种疾病的腹部症状可能会重叠，使得鉴别诊断和治疗具有挑战性。中草药组合制剂STW 5(Iberogast(R))的提取物在不同的胃肠道发挥药理作用，可以治疗FD和IBS的症状。该综述总结了自1990年以来使用STW 5治疗FD和IBS的12项临床试验的安全性和有效性数据。与安慰剂或主动对照相比的双盲随机研究发现，STW 5对患者症状的影响具有统计学意义，其疗效与标准促动力药相当。非干预性和回顾性研究证实了这些影响。多项研究评估了STW 5的耐受性：不良反应发生率为0.04%。全球自发报告系统证实了这一情况。STW-5具有良好的耐受性，这与长期治疗有关。
Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are frequent disorders affecting quality of life. They often require long-term treatment. Abdominal symptoms of both disorders can overlap, making differential diagnosis and treatment challenging. The extracts of the herbal combination preparation STW 5 (Iberogast (R)) exert pharmacological effects in different gastrointestinal regions and can address symptoms of both FD and IBS. This review summarizes safety and efficacy data of 12 clinical trials using STW 5 in FD and IBS since 1990. Double-blind and randomized studies versus placebo or active control found statistically significant effects of STW 5 on patients' symptoms with a comparable efficacy to a standard prokinetic. Non-interventional and retrospective studies confirmed these effects. Various studies evaluated the tolerability profile of STW 5: the incidence of adverse drug reactions was 0.04 %. The worldwide spontaneous reporting system confirmed this profile. STW 5 has a favorable tolerability which is relevant for long-term treatment.